Rigorously tested and continuously validated in practice, Cytel software is used at thousands of pharmaceutical, biotech, medical device companies, and leading independent research institutes.
Cytel’s cutting-edge trial design and implementation expertise, with a specialty in adaptive trials, is helping sponsor companies of all sizes to increase success rates in clinical development.
SCOPE February 24: Enrollment Planning and Patient Recruitment
Will your trial enroll the needed patients in time? Cytel unveils simulation-based trial enrollment forecasting advances. Go to the Cytel booth for software demos and further information.
March 24 - 26, Boston Cyrus Mehta Reveals Lessons Learned from Adaptive Trials in Oncology
“Adaptive Oncology Trials with Time to Event Endpoints” by Cytel President & Co-Fonder Cyrus Mehta chronicles the impact of adaptive approaches in oncology clinical development.
What Clients Say
--Simona Skerjanec, VP Medical Science
The Medicines Company
--Steven B. Ketchum, VP Research and Development
--Joe Heyes, VP
Early Stage Biostatistics Merck
--Dr. Scott Harris, CMO
--Dr. Patrice Rioux, VP, CMO
--Sylvain Nicolas, Global Head Biostatistics Phase 1 Studies